TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects on Growth and Tolerance of Hydrolyzed Formulas Fed to Term Infants
Brief Summary: A study to evaluate the growth and development of term infants fed either an extensively hydrolyzed formula with probiotics, a partially hydrolyzed formula with probiotics, or an extensively hydrolyzed formula without probiotics


Options:
A: Arm Label: extensively hydrolyzed casein formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: dietary intervention | Arm Label: cow's milk based infant formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: dietary intervention | Intervention Type: DIETARY_SUPPLEMENT; Name: dietary intervention; Assigned to Arm(s): cow's milk based infant formula, extensively hydrolyzed casein formula
B: Arm Label: Group EEEEEEE; Type: ACTIVE_COMPARATOR; Interventions: Other: Enfamil, milk-based formula | Arm Label: Group ENEEEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group EENEEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group EEENEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group ENNNEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group NNNNNNN; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Intervention Type: OTHER; Name: Nutramigen (Flavor and Type of Infant Formula); Assigned to Arm(s): Group EEENEEE, Group EENEEEE, Group ENEEEEE, Group ENNNEEE, Group NNNNNNN | Intervention Type: OTHER; Name: Enfamil, milk-based formula; Assigned to Arm(s): Group EEEEEEE
C: Arm Label: Hydrolysed infant formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Hydrolysed infant formula | Arm Label: Nonhydrolysed infant formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Nonhydrolysed infant formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Hydrolysed infant formula; Assigned to Arm(s): Hydrolysed infant formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Nonhydrolysed infant formula; Assigned to Arm(s): Nonhydrolysed infant formula
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: infant formula | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: infant formula | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: infant formula | Intervention Type: OTHER; Name: infant formula; Assigned to Arm(s): 1, 2, 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects on Growth and Tolerance of Hydrolyzed Formulas Fed to Term Infants
Brief Summary: A study to evaluate the growth and development of term infants fed either an extensively hydrolyzed formula with probiotics, a partially hydrolyzed formula with probiotics, or an extensively hydrolyzed formula without probiotics


Options:
A: Arm Label: Cow's milk formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cow's milk formula | Arm Label: Bovine insulin-free whey based formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cow's milk formula | Arm Label: Whey-based hydrolysed formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cow's milk formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Cow's milk formula; Assigned to Arm(s): Bovine insulin-free whey based formula, Cow's milk formula, Whey-based hydrolysed formula
B: Arm Label: Hydrolysed infant formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Hydrolysed infant formula | Arm Label: Nonhydrolysed infant formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Nonhydrolysed infant formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Hydrolysed infant formula; Assigned to Arm(s): Hydrolysed infant formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Nonhydrolysed infant formula; Assigned to Arm(s): Nonhydrolysed infant formula
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: infant formula | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: infant formula | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: infant formula | Intervention Type: OTHER; Name: infant formula; Assigned to Arm(s): 1, 2, 3
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Enfamil LIPIL with iron | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Good Start Supreme with DHA and ARA | Intervention Type: OTHER; Name: Enfamil LIPIL with iron; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Good Start Supreme with DHA and ARA; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects on Growth and Tolerance of Hydrolyzed Formulas Fed to Term Infants
Brief Summary: A study to evaluate the growth and development of term infants fed either an extensively hydrolyzed formula with probiotics, a partially hydrolyzed formula with probiotics, or an extensively hydrolyzed formula without probiotics


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: infant formula | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: infant formula | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: infant formula | Intervention Type: OTHER; Name: infant formula; Assigned to Arm(s): 1, 2, 3
B: Arm Label: Cow's milk formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cow's milk formula | Arm Label: Bovine insulin-free whey based formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cow's milk formula | Arm Label: Whey-based hydrolysed formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cow's milk formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Cow's milk formula; Assigned to Arm(s): Bovine insulin-free whey based formula, Cow's milk formula, Whey-based hydrolysed formula
C: Arm Label: Hydrolysed infant formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Hydrolysed infant formula | Arm Label: Nonhydrolysed infant formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Nonhydrolysed infant formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Hydrolysed infant formula; Assigned to Arm(s): Hydrolysed infant formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Nonhydrolysed infant formula; Assigned to Arm(s): Nonhydrolysed infant formula
D: Arm Label: Group EEEEEEE; Type: ACTIVE_COMPARATOR; Interventions: Other: Enfamil, milk-based formula | Arm Label: Group ENEEEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group EENEEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group EEENEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group ENNNEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group NNNNNNN; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Intervention Type: OTHER; Name: Nutramigen (Flavor and Type of Infant Formula); Assigned to Arm(s): Group EEENEEE, Group EENEEEE, Group ENEEEEE, Group ENNNEEE, Group NNNNNNN | Intervention Type: OTHER; Name: Enfamil, milk-based formula; Assigned to Arm(s): Group EEEEEEE

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind, Crossover, Placebo-Controlled Clinical Trial to Assess the Effects of a Mouthwash Containing Chlorine Dioxide on Oral Malodor
Brief Summary: A mouthwash containing chlorine dioxide would be effective to reduce oral malodor.


Options:
A: Arm Label: group 1: drug; Type: EXPERIMENTAL; Interventions: Drug: group 1: drug: chlorine dioxide | Arm Label: group 2: device:; Type: EXPERIMENTAL; Interventions: Device: group 2: device: small tooth brush for tongue cleaning | Intervention Type: DRUG; Name: group 1: drug: chlorine dioxide; Assigned to Arm(s): group 1: drug | Intervention Type: DEVICE; Name: group 2: device: small tooth brush for tongue cleaning; Assigned to Arm(s): group 2: device:
B: Intervention Type: OTHER; Name: Chlorine Dioxide; Assigned to Arm(s): N/A
C: Intervention Type: OTHER; Name: Chlorine Dioxide; Assigned to Arm(s): N/A
D: Arm Label: test; Type: EXPERIMENTAL; Interventions: Device: glycine powder air-polishing (Air-Flows)Perio Powder, Device: ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Device: ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) | Intervention Type: DEVICE; Name: glycine powder air-polishing (Air-Flows)Perio Powder; Assigned to Arm(s): test | Intervention Type: DEVICE; Name: ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland); Assigned to Arm(s): control, test

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Modulation of Lung Injury Complicating Lung Resection
Brief Summary: The purpose of this study is to determine whether N-acetylcysteine given intravenously 1 day pre-operatively is effective in preventing inflammation in the lungs, as measured by tests on blood, breath and lung specimens, in patients undergoing surgery to remove a portion of lung.


Options:
A: Arm Label: N-acetylcysteine; Type: EXPERIMENTAL; Interventions: Drug: N-acetylcysteine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% saline | Intervention Type: DRUG; Name: N-acetylcysteine; Assigned to Arm(s): N-acetylcysteine | Intervention Type: DRUG; Name: 0.9% saline; Assigned to Arm(s): Placebo
B: Arm Label: No dexamethasone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone
C: Intervention Type: DRUG; Name: Xigris; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: HL 10; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis
Brief Summary: The purpose of this study is to determine the safety and tolerability of the MDX-1100 regimen in subjects with active Ulcerative colitis(UC) and determine the response rate at day 57 in patients administered MDX-1100.


Options:
A: Intervention Type: DRUG; Name: mesalazine; Assigned to Arm(s): N/A
B: Arm Label: 30 children with UC; Type: N/A; Interventions: N/A
C: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: sterile saline for injection | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: MDX-1100 | Intervention Type: BIOLOGICAL; Name: sterile saline for injection; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: MDX-1100; Assigned to Arm(s): 1
D: Arm Label: PLC Colon release tablet 1 g; Type: EXPERIMENTAL; Interventions: Drug: Propionyl-L-Carnitine, Drug: Placebo | Arm Label: PLC colon release tablet 2 g; Type: EXPERIMENTAL; Interventions: Drug: Propionyl-L-Carnitine, Drug: Placebo | Arm Label: Placebo PLC colon release tablet 2 g; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Propionyl-L-Carnitine; Assigned to Arm(s): PLC Colon release tablet 1 g | Intervention Type: DRUG; Name: Propionyl-L-Carnitine; Assigned to Arm(s): PLC colon release tablet 2 g | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLC Colon release tablet 1 g, PLC colon release tablet 2 g, Placebo PLC colon release tablet 2 g

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Orally Administered 220 mg Dabigatran Etexilate Capsules (110 mg Administered on the Day of Surgery Followed by 220 mg Once Daily) Compared to Subcutaneous 40 mg Enoxaparin Once Daily for 28-35 Days, in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip Arthroplasty Surgery. (RE-NOVATE II)
Brief Summary: The primary objective of the trial is to demonstrate non-inferiority of 220 mg oral dabigatran etexilate compared to 40 mg subcutaneous enoxaparin administered once daily. Safety and efficacy will be compared between the treatment groups.


Options:
A: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate low dose, Drug: dabigatran etexilate intermediate dose, Drug: dabigatran etexilate high dose | Arm Label: warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin 5mg, Drug: warfarin 1mg, Drug: warfarin 3mg | Intervention Type: DRUG; Name: dabigatran etexilate low dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 5mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate intermediate dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 1mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate high dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 3mg; Assigned to Arm(s): warfarin
B: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate intermediate dose, Drug: dabigatran etexilate low dose, Drug: dabigatran etexilate high dose | Arm Label: warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin 1mg, Drug: warfarin 5mg, Drug: warfarin 3mg | Intervention Type: DRUG; Name: warfarin 1mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate intermediate dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: dabigatran etexilate low dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 5mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate high dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 3mg; Assigned to Arm(s): warfarin
C: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Orally Administered 220 mg Dabigatran Etexilate Capsules (110 mg Administered on the Day of Surgery Followed by 220 mg Once Daily) Compared to Subcutaneous 40 mg Enoxaparin Once Daily for 28-35 Days, in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip Arthroplasty Surgery. (RE-NOVATE II)
Brief Summary: The primary objective of the trial is to demonstrate non-inferiority of 220 mg oral dabigatran etexilate compared to 40 mg subcutaneous enoxaparin administered once daily. Safety and efficacy will be compared between the treatment groups.


Options:
A: Intervention Type: PROCEDURE; Name: Bilateral ultrasound examination 7+/- 2 after surgery; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (BAY59-7939) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban (BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Arm 2
C: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate
D: Arm Label: dabigatran etexilate 75 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate | Arm Label: dabigatran etexilate 110 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate | Arm Label: enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate 75 mg | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate 110 mg | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): enoxaparin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of 3 Months Daily Treatment With Selective Serotonin Reuptake Inhibitor (SSRI, Fluoxetine) on Motor Rehabilitation After Ischemic Stroke. FLAME Trial
Brief Summary: Recovery from stroke is a major process and, except for acute intravenous thrombolysis, no treatment able to enhance recovery has yet been validated. Some drugs may have a positive effect when combined with physical rehabilitation. Previous studies have shown a potential effect of catecholaminergic drugs on cerebral plasticity of stroke patients. In 2001, our group has demonstrated in a small group of stroke patients (n=8) that a single dose of fluoxetine (Selective Serotonin Reuptake Inhibitor - SSRI) improved motor performance and modulated cerebral plasticity. We conducted a phase IIb prospective, double-blind, randomized, placebo controlled study to assess the effect of a daily treatment with fluoxetin (20 mg) on motor performance in patients with mild to severe motor deficit after ischemic stroke.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fluoxetine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: intravenous tissue plasminogen activator; Type: EXPERIMENTAL; Interventions: Drug: Alteplase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Alteplase; Assigned to Arm(s): intravenous tissue plasminogen activator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: TMS; Type: EXPERIMENTAL; Interventions: Device: TMS | Intervention Type: DEVICE; Name: TMS; Assigned to Arm(s): TMS

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of 3 Months Daily Treatment With Selective Serotonin Reuptake Inhibitor (SSRI, Fluoxetine) on Motor Rehabilitation After Ischemic Stroke. FLAME Trial
Brief Summary: Recovery from stroke is a major process and, except for acute intravenous thrombolysis, no treatment able to enhance recovery has yet been validated. Some drugs may have a positive effect when combined with physical rehabilitation. Previous studies have shown a potential effect of catecholaminergic drugs on cerebral plasticity of stroke patients. In 2001, our group has demonstrated in a small group of stroke patients (n=8) that a single dose of fluoxetine (Selective Serotonin Reuptake Inhibitor - SSRI) improved motor performance and modulated cerebral plasticity. We conducted a phase IIb prospective, double-blind, randomized, placebo controlled study to assess the effect of a daily treatment with fluoxetin (20 mg) on motor performance in patients with mild to severe motor deficit after ischemic stroke.


Options:
A: Arm Label: SSRI; Type: EXPERIMENTAL; Interventions: Drug: SSRI | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SSRI; Assigned to Arm(s): SSRI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: sugar pill | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): escitalopram | Intervention Type: DRUG; Name: sugar pill; Assigned to Arm(s): placebo
C: Arm Label: 1 Problem Solving Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy | Arm Label: 2. Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): 1 Problem Solving Therapy | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): 2. Escitalopram | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3 Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fluoxetine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: D